Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located
in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical
efficacy has been shown in adult with head and neck cancer. The study assessed the efficacy
and safety of the combination of Nimotuzumab administered concomitantly with
chemoradiotherapy in patients with NSCLC .There is a tolerance trial of Nimotuzumab in
Combination With Radiochemotherapy treatment before the randomization,double
blind,muti-center sites trial of this treatment.